To confirm my understanding of this paragraph:
It is stating that since a patient gets diagnosed there is a 22%-34% mortality within 1 year. In our trial out of the 12 patients who have been diagnosed about 29.9 months (some up to 50 months!) and on this drug for the last 19 months, there has been no safety concerns let alone mortality. Is that correct? Hurray!
Ann: Final Ethics Approval for Open-Label MND Extension Study, page-6
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $141.2K | 801.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537419 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 140000 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |